Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway

Nephrology Dialysis Transplantation

Volumn 29, Issue 11, 2014, Pages 2043-2053

  Kim, Dal ^a   Lee, Ae Sin ^a   Jung, Yu Jin ^a   Yang, Kyoung Hee ^a   Lee, Sik ^a   Park, Sung Kwang ^a   Kim, Won ^a   Kang, Kyung Pyo ^a  

^a Jeonbuk National University Medical School and Hospital   (South Korea)

Author keywords

Estrogen receptor ; Fibroblast; Inflammation; Kidney fibrosis; Transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELL ADHESION MOLECULE; COLLAGEN TYPE 1; ESTROGEN RECEPTOR ALPHA; FIBRONECTIN; SMAD PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN; ANTIESTROGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; URETER LIGATION; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FIBROSIS; METABOLISM; NEPHRITIS, INTERSTITIAL; PATHOLOGY; RAT;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; NEPHRITIS, INTERSTITIAL; RATS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84924026400     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu240     Document Type: Article

References (41)

1. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-1834
2. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014;85:49-61
3. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 2009;296:F1239-F1244
4. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011;7:684-696
5. Gewin L, Zent R. How does TGF-beta mediate tubulointerstitial fibrosis? Semin Nephrol 2012;32:228-235
6. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012;32:236-243
7. Casalena G, Daehn I, Bottinger E. Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin Nephrol 2012;32:295-303
8. Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102:593-608
9. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009;19:128-139
10. Matsuda T, Yamamoto T, Muraguchi A et al. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001;276:42908-42914
11. Ito I, Hanyu A, Wayama M et al. Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 2010;285:14747-14755
12. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissuespecific agonist and antagonist actions. Steroids 2002;67:15-24
13. Sugerman DT. JAMA patient page. Tamoxifen update. JAMA 2013;310:866
14. Rosell J, Nordenskjold B, Bengtsson NO et al. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with longterm follow-up. Breast Cancer Res Treat 2013;138:467-473
15. Kanis JA, Johansson H, Oden A et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729-735
16. van Bommel EF, Pelkmans LG, van Damme H et al. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 2013;24:444-450
17. Korte MR, Fieren MW, Sampimon DE et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 2011;26:691-697
18. Savelli BA, Parshley M, Morganroth ML. Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Chest 1997;111:1137-1140
19. Hansmann A, Adolph C, Vogel T et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620
20. Ruffy MB, Kunnavatana SS, Koch RJ. Effects of tamoxifen on normal human dermal fibroblasts. Arch Facial Plast Surg 2006;8:329-332
21. Neugarten J, Acharya A, Lei J et al. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 2000;279:F309-F318
22. Delle H, Rocha JR, Cavaglieri RC et al. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol 2012;23:37-48
23. Kim W, Moon SO, Lee SY et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 2006;17:2474-2483
24. Kim DH, Moon SO, Jung YJ et al. Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 2009;75:1031-1038
25. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-3393
26. Kang KP, Park SK, Kim DH et al. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol Dial Transplant 2011;26:814-822
27. Zhang H, Sun L, Wang W et al. Quantitative analysis of fibrosis formation on the microcapsule surface with the use of picro-sirius red staining, polarized light microscopy, and digital image analysis. J Biomed Mater Res A 2006;76:120-125
28. Chuang PY, Menon MC, He JC. Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) 2013;91:549-559
29. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210
30. Bani-Hani AH, Campbell MT, Meldrum DR et al. Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy. J Urol 2008;180:461-468
31. Misseri R, Rink RC, Meldrum DR et al. Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res 2004;119:149-159
32. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010;6:643-656
33. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009;5:319-328
34. Rohatgi R, Flores D. Intratubular hydrodynamic forces influence tubulointerstitial fibrosis in the kidney. Curr Opin Nephrol Hypertens 2010;19:65-71
35. Alikhan MA, Ricardo SD. Mononuclear phagocyte system in kidney disease and repair. Nephrology (Carlton) 2013;18:81-91
36. de Jong JP, Leenen PJ, Voerman JS et al. A monoclonal antibody (ER-HR3) against murine macrophages. II. Biochemical and functional aspects of the ER-HR3 antigen. Cell Tissue Res 1994;275:577-585
37. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007;101:9-33
38. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999;9:274-279
39. Kang HY, Lin HK, Hu YC et al. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci U S A 2001;98:3018-3023
40. Subramaniam N, Leong GM, Cock TA et al. Cross-talk between 1, 25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001;276:15741-15746
41. Pierce GF, Mustoe TA, Lingelbach J et al. Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc Natl Acad Sci U S A 1989;86:2229-2233